The Nucleic Acid Labelling Market size in North America is estimated to be worth USD 994.64 million by 2027 from USD 670.7 million in 2022, growing at a CAGR of 8.20% during the forecast period.
The North American Nucleic Acid Labelling Market is expected to be driven by introducing advanced products offering pertain nucleic acid detection and penetration of nucleic acid labels to set witness elevation across DNA Microarrays. Also, expanding pool of commercial manufacturers strengthens the revenue generation capacity of the nucleic acid labelling industry.
Recent developments in the nanotechnology sector have substantially improved nucleic acid detection at the point of care (POC). POC solutions might be used to detect RNA and DNA in a portable format; for example, this makes it appealing to individuals working in various healthcare fields, including on-site detection and bedside/patient side diagnosis. Reviewing recent developments targeted at examining the utilization of read-out modalities, sample preparation, and target amplification are examples of research initiatives along these lines. As a result of the introduction of innovative nanotechnology technologies, point-of-care nucleic acid detection is expected to acquire significant momentum inaccessible and decentralized testing, propelling the market forward.
In the life sciences sector, nucleic acid tagging methods have a wide range of uses. Using different labelling techniques, nucleic acid labelling is primarily used to identify proteins, DNA, and RNA. Multiple labels for specific applications are currently available on the market.
The key to identifying individual compounds is to use the right labelling technique strategy. Previously, radioactive labelling techniques dominated the market. Radioactive methods, on the other hand, are less popular due to safety concerns. As a result of its great sensitivity and safety concerns, non-radioactive labelling methods are gaining popularity for accurately identifying molecules.
On the other hand, increasing healthcare expenditure, availability of healthcare infrastructure, and surging demand for personalized healthcare are rapidly increasing the market growth. In addition, the major companies in the region are conducting research and development activities on genomics, and the rise in disease diagnosis is driving the market growth.
Chemiluminescent and chemifluorescent methods have replaced the use of radioactive materials to identify antibodies in the non-radioactive category. Several firms are focusing on developing nucleic acid labelling test kits for a variety of applications. Major diagnostic firms are designing nucleic acid test kits. The significant firms dominate the nucleic acid labelling market, with medium and small players coming in second and fourth.
However, the lack of skilled professionals in the transcriptomics field and expensive processing techniques restrict the North American nucleic acid labelling market growth.
This research report on the North America Nucleic Acid Labelling Market has been segmented and sub-segmented into the following categories:
By Labelling Technique:
By End Users:
Geographically, North America dominated the global Nucleic Acid Labelling Market and is likely to continue its dominance throughout the forecast period. The market in the region is mostly driven by technological advancements in the healthcare sector, favorable reimbursement policies, and growing concern among the people about healthcare. Also, with the healthcare spending, increasing research activities in genomics research and disease diagnosis are the other major growth factors influencing the market. As a result, the countries such as the United States and Canada are expanding the market with significant market share. Over the forecast period, the United States accounted substantial share in the market. The nucleic acid labelling market’s revenue-generating capability is strengthened by introducing improved product offerings in nucleic acid detection and the growing pool of commercial manufacturers. Moreover, considering the rising prevalence of genetic disorders, healthcare professionals are keen on investing in developing products related to nucleic acid analytics, which is expected to expand the market growth in the U.S.
On the other hand, the Canadian Nucleic Acid Labelling Market is projected to witness a moderate market share and contribute to the regional market expansion.
KEY MARKET PLAYERS:
A few of the prominent companies dominating the North America Nucleic Acid Labelling Market include Thermo Fisher Scientific, New England Biolabs, PerkinElmer, F. Hoffmann La-Roche AG, General Electric Company, Merck KGaA, Enzo Biochem, Promega Corporation, Vector Laboratories, and Agilent Technologies.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org